|
1
|
Mcmanus DD, Gore J, Yarzebski J, Spencer
F, Lessard D and Goldberg RJ: Recent trends in the incidence,
treatment, and outcomes of patients with STEMI and NSTEMI. Am J
Med. 124:40–47. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Pontecorboli G, Ventura RMFI, Carlosena A,
Benito EM, Pratgonzales S, Padeletti L and Mont L: Use of
delayed-enhancement magnetic resonance imaging for fibrosis
detection in the atria: A review. Europace. 19:180–189.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Nagalingam RS, Safi HA and Czubryt MP:
Gaining myocytes or losing fibroblasts: Challenges in cardiac
fibroblast reprogramming for infarct repair. J Mol Cell Cardiol.
93:108–114. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tahrani AA, Barnett AH and Bailey CJ: SGLT
inhibitors in management of diabetes. Lancet Diabetes Endocrinol.
1:140–151. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wells RG, Mohandas TK and Hediger MA:
Localization of the Na+/glucose cotransporter gene SGLT2 to human
chromosome 16 close to the centromere. Genomics. 17:787–789.
1993.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kashiwagi Y, Nagoshi T, Yoshino T, Tanaka
TD, Ito K, Harada T, Takahashi H, Ikegami M, Anzawa R and Yoshimura
M: Expression of SGLT1 in human hearts and impairment of cardiac
glucose uptake by phlorizin during ischemia-reperfusion injury in
mice. PLoS One. 10(e0130605)2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Koepsell H: The Na(+)-D-glucose
cotransporters SGLT1 and SGLT2 are targets for the treatment of
diabetes and cancer. Pharmacol Ther. 170:148–165. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Furtado RHM, Bonaca MP, Raz I, Zelniker
TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, et
al: Dapagliflozin and cardiovascular outcomes in patients with type
2 diabetes mellitus and previous myocardial infarction.
Circulation. 139:2516–2527. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Reid J, Rana K, Niman S, Sheikh-Ali M,
Lewis T, Choksi RR and Goldfaden RF: Sodium-glucose cotransporter-2
(SGLT-2) inhibitors for cardiovascular disease prevention. Am J
Cardiovasc Drugs. 20:419–429. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zinman B, Wanner C, Lachin JM, Fitchett D,
Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ,
et al: Empagliflozin, cardiovascular outcomes, and mortality in
type 2 diabetes. N Engl J Med. 373:2117–2128. 2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Habibi J, Aroor AR, Sowers JR, Jia G,
Hayden MR, Garro M, Barron BJ, Mayoux E, Rector RS, Whaley-Connell
A and DeMarco VG: Sodium glucose transporter 2 (SGLT2) inhibition
with empagliflozin improves cardiac diastolic function in a female
rodent model of diabetes. Cardiovasc Diabetol. 16(9)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ye Y, Bajaj M, Yang HC, Perez-Polo JR and
Birnbaum Y: SGLT-2 inhibition with dapagliflozin reduces the
activation of the Nlrp3/ASC inflammasome and attenuates the
development of diabetic cardiomyopathy in mice with type 2
diabetes. Further augmentation of the effects with saxagliptin, a
DPP4 inhibitor. Cardiovasc Drugs Ther. 31:119–132. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Piccoli MT, Bar C and Thum T: Non-coding
RNAs as modulators of the cardiac fibroblast phenotype. J Mol Cell
Cardiol. 92:75–81. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wang H, Zhang X, Li Y, Ma Y, Zhang Y, Liu
Z, Zhou J, Lin Q, Wang Y, Duan C and Wang C: Improved myocardial
performance in infarcted rat heart by co-injection of basic
fibroblast growth factor with temperature-responsive chitosan
hydrogel. J Heart Lung Transplant. 29:881–887. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yuan J, Chen H, Ge D, Xu Y, Xu H, Yang Y,
Gu M, Zhou Y, Zhu J, Ge T, et al: Mir-21 promotes cardiac fibrosis
after myocardial infarction via targeting Smad7. Cell Physiol
Biochem. 42:2207–2219. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Hao K, Lei W, Wu H, Wu J, Yang Z, Yan S,
Lu XA, Li J, Xia X, Han X, et al: LncRNA-Safe contributes to
cardiac fibrosis through Safe-Sfrp2-HuR complex in mouse myocardial
infarction. Theranostics. 9:7282–7297. 2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Wang H, Qi C and Wan D: MicroRNA-377-3p
targeting MMP-16 inhibits ovarian cancer cell growth, invasion, and
interstitial transition. Ann Transl Med. 9(124)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Guo J, Gan Q, Gan C, Zhang X, Ma X and
Dong M: LncRNA MIR205HG regulates melanomagenesis via the
miR-299-3p/VEGFA axis. Aging (Albany NY). 13:5297–5311.
2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wu H, Zhou X, Wang X, Cheng W, Hu X, Wang
Y, Luo B, Huang W and Gu J: miR-34a in extracellular vesicles from
bone marrow mesenchymal stem cells reduces rheumatoid arthritis
inflammation via the cyclin I/ATM/ATR/p53 axis. J Cell Mol Med.
25:1896–1910. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Qu X, Du Y, Shu Y, Gao M, Sun F, Luo S,
Yang T, Zhan L, Yuan Y, Chu W, et al: MIAT is a pro-fibrotic long
non-coding RNA governing cardiac fibrosis in post-infarct
myocardium. Sci Rep. 7(42657)2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhou B and Yu JW: A novel identified
circular RNA, circRNA_010567, promotes myocardial fibrosis via
suppressing miR-141 by targeting TGF-β1. Biochem Biophys Res
Commun. 487:769–775. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Travers JG, Kamal FA, Robbins J, Yutzey KE
and Blaxall BC: Cardiac fibrosis: The fibroblast awakens. Circ Res.
118:1021–1040. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Moore-Morris T, Guimaraes-Camboa N, Yutzey
KE, Puceat M and Evans SM: Cardiac fibroblasts: From development to
heart failure. J Mol Med (Berl). 93:823–830. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Leask A: Getting to the heart of the
matter new insights into cardiac fibrosis. Circ Res. 116:1269–1276.
2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Schelbert EB, Fonarow GC, Bonow RO, Butler
J and Gheorghiade M: Therapeutic targets in heart failure:
Refocusing on the myocardial interstitium. J Am Coll Cardiol.
63:2188–2198. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Okada J, Yamada E, Saito T, Yokoo H, Osaki
A, Shimoda Y, Ozawa A, Nakajima Y, Pessin JE, Okada S and Yamada M:
Dapagliflozin inhibits cell adhesion to collagen I and IV and
increases ectodomain proteolytic cleavage of DDR1 by increasing
ADAM10 activity. Molecules. 25(495)2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Grimaldi V, De Pascale MR, Zullo A,
Soricelli A, Infante T, Mancini FP and Napoli C: Evidence of
epigenetic tags in cardiac fibrosis. J Cardiol. 69:401–408.
2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Cheng R, Dang R, Zhou Y, Ding M and Hua H:
MicroRNA-98 inhibits TGF-β1-induced differentiation and collagen
production of cardiac fibroblasts by targeting TGFBR1. Human Cell.
30:192–200. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Van Rooij E, Sutherland LB, Thatcher JE,
Dimaio JM, Naseem RH, Marshall WS, Hill JA and Olson EN:
Dysregulation of microRNAs after myocardial infarction reveals a
role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA.
105:13027–13032. 2008.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Li L, Bounds KR, Chatterjee P and Gupta S:
MicroRNA-130a, a potential antifibrotic target in cardiac fibrosis.
J Am Heart Assoc. 6(e006763)2017.PubMed/NCBI View Article : Google Scholar
|
